Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company

Journal of Human Hypertension volume 36, pages 308–314 (2022)Cite this article

Subjects

Abstract

The aim of our study was to evaluate the prevalence, awareness, and control of hypertension in an apparently healthy company population. We conducted a cross-sectional study on a total sample of 2058 individuals with a mean age of 38 ± 9 years, enrolled for the first time to the Ferrari corporate wellness program “Formula Benessere”. Hypertension was defined as systolic blood pressure (SBP) level ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg or use of antihypertensive medication, whereas BP control was defined as BP level <130/80 mmHg. All 2058 participants were divided into three groups based on age: Group 1 aged <40 years (n = 1177, 57%), Group 2 aged 40–50 years (n = 627, 30%), and Group 3 aged >50 years (n = 254, 13%). Four-hundred and one subjects had BP levels ≥130/80 mmHg (19.5%). Two-hundred and sixty-one individuals (12.7%) had high-normal BP values and 140 subjects had rest SBP ≥140 mmHg and/or DBP ≥90 mmHg (6,8%), of which 41 (29.3%) with grade 2 hypertension. In the overall population, 259 individuals (12.5%) were affected by hypertension, the prevalence increasing with age. Only a minority (51%) was aware of being hypertensive and already treated with antihypertensive medications (45.9%). An adequate BP control was achieved in only 57% of subjects who received BP-lowering therapy. Corporate wellness programs may represent an essential tool in identifying apparently healthy subjects with an inadequate control of cardiovascular (CV) risk factors, such as hypertension. These preventive programs in the workplace may help to improve and spread primary CV prevention at the population level.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Hypertension prevalence, awareness, treatment, and control rates in the overall population and in the different groups based on age.

Similar content being viewed by others

References

  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13. https://doi.org/10.1016/s0140-6736(02)11911-8.

    Article  PubMed  Google Scholar 

  2. Redon J, Mourad JJ, Schmieder RE, Volpe M, Weiss TW. Why in 2016 are patients with hypertension not 100% controlled? A call to action. J Hypertens. 2016;34:1480–1488. https://doi.org/10.1097/HJH.0000000000000988.

    Article  CAS  PubMed  Google Scholar 

  3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260. https://doi.org/10.1016/S0140-6736(12)61766-8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Biffi A, Fernando F, Adami PE, Messina M, Sirico F, Di Paolo F, et al. Ferrari corporate wellness program: results of a pilot analysis and the "Drag" impact in the workplace. High Blood Press Cardiovasc Prev. 2018;25:261–6.

    Article  Google Scholar 

  5. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.

    Article  Google Scholar 

  6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138:e484–e594. https://doi.org/10.1161/CIR.0000000000000596.

    Article  PubMed  Google Scholar 

  7. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017;389:37–55.

    Article  Google Scholar 

  8. Tocci G, Muiesan ML, Parati G, Agabiti Rosei E, Ferri C, Virdis A, et al. Trends in prevalence, awareness, treatment, and control of blood pressure recorded from 2004 to 2014 During World Hypertension Day in Italy. J Clin Hypertens (Greenwich). 2016;18:551–6.

    Article  Google Scholar 

  9. Rahimi K, Emdin CA, MacMahon S. The epidemiology of blood pressure and its worldwide management. Circ Res. 2015;116:925–36.

    Article  CAS  Google Scholar 

  10. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383:1912–9.

    Article  Google Scholar 

  11. Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, et al. Blood pressure control in Italy: analysis of clinical data from 2005-11 surveys on hypertension. J Hypertens. 2012;30:1065–74.

    Article  CAS  Google Scholar 

  12. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394:639–51.

    Article  Google Scholar 

  13. Lee JH, Kim SH, Kang SH, Cho JH, Cho Y, Oh I, et al. Blood pressure control and cardiovascular outcomes: real-world implications of the 2017 ACC/AHA hypertension guideline. Sci Rep. 2018;8:13155. https://doi.org/10.1038/s41598-018-31549-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Brunström M, Ng N, Dahlström J, Lindholm LH, Lönnberg G, Norberg M, et al. Association of physician education and feedback on hypertension management with patient blood pressure and hypertension control. JAMA Netw Open. 2020;3:e1918625. https://doi.org/10.1001/jamanetworkopen.2019.18625.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Redon J, Mourad JJ, Schmieder RE, Volpe M, Weiss TW. Why in 2016 are patients with hypertension not 100% controlled? A call to action. J Hypertens. 2016;34:1480–8.

    Article  CAS  Google Scholar 

  16. Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens. 2017;31:258–62.

    Article  CAS  Google Scholar 

  17. Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management? Int J Cardiol. 2018;254:328–32.

    Article  Google Scholar 

  18. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67. https://doi.org/10.1016/S0140-6736(15)01225-8.

    Article  PubMed  Google Scholar 

  19. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–43. https://doi.org/10.1016/S0140-6736(15)00805-3.

    Article  PubMed  Google Scholar 

  20. Hinton TC, Adams ZH, Baker RP, Hope KA, Paton JFR, Hart EC, et al. Investigation and treatment of high blood pressure in young people: too much medicine or appropriate risk reduction? Hypertension. 2020;75:16–22.

    Article  CAS  Google Scholar 

  21. Gu A, Yue Y, Argulian E. Age Differences in treatment and control of hypertension in US physician offices, 2003-10: a serial cross-sectional study. Am J Med. 2016;129:50–58.e4. https://doi.org/10.1016/j.amjmed.2015.07.031.

    Article  PubMed  Google Scholar 

  22. Volpe M, Gallo G, Tocci G. Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: room for monotherapy? Int J Cardiol. 2019;291:105–111. https://doi.org/10.1016/j.ijcard.2019.04.074.

    Article  PubMed  Google Scholar 

  23. Torlasco C, Faini A, Makil E, Bilo G, Pengo M, Beaney T, et al. Nation-wide hypertension screening in Italy: data from May Measurements Month 2017-Europe. Eur Heart J Suppl. 2019;21:D66–70. https://doi.org/10.1093/eurheartj/suz058.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Padwal RS, Bienek A, McAlister FA, Campbell NR. Outcomes research task force of the Canadian hypertension education program. Epidemiology of hypertension in Canada: an update. Can J Cardiol. 2016;32:687–94.

    Article  Google Scholar 

  25. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310:699–705.

    Article  CAS  Google Scholar 

  26. Otsuka T, Takada H, Nishiyama Y, Kodani E, Saiki Y, Kato K, et al. Dyslipidemia and the risk of developing hypertension in a working-age male population. J Am Heart Assoc. 2016;5:e003053. https://doi.org/10.1161/JAHA.115.003053.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Borghi C, Veronesi M, Bacchelli S, Esposti DD, Cosentino E, Ambrosioni E. Serum cholesterol levels, blood pressure response to stress and incidence of stable hypertension in young subjects with high normal blood pressure. J Hypertens. 2004;22:265–72.

    Article  CAS  Google Scholar 

  28. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228–34.

    Article  CAS  Google Scholar 

  29. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–798. https://doi.org/10.1161/CIRCULATIONAHA.105.548206.

    Article  PubMed  Google Scholar 

  30. Andersson C, Johnson AD, Benjamin EJ, Levy D, Vasan RS. 70-year legacy of the Framingham heart study. Nat Rev Cardiol. 2019;16:687–98. https://doi.org/10.1038/s41569-019-0202-5.

    Article  PubMed  Google Scholar 

  31. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. https://doi.org/10.1093/eurheartj/ehz455.

    Article  PubMed  Google Scholar 

  32. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013;15:14–33. https://doi.org/10.1111/jch.12049.

    Article  CAS  Google Scholar 

  33. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116:991–1006. https://doi.org/10.1161/CIRCRESAHA.116.305697.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Alessandro Biffi, Giovanna Gallo

Authors and Affiliations

  1. Med-Ex, Medicine & Exercise srl, Rome, Italy

    Alessandro Biffi, Fredrick Fernando, Felice Sirico, Maria Grazia Signorello, Michele Messina, Giorge Manole & Nicola Triglione

  2. Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy

    Giovanna Gallo & Massimo Volpe

  3. IRCCS Neuromed, Pozzilli, IS, Italy

    Massimo Volpe

Authors
  1. Alessandro Biffi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanna Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fredrick Fernando
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felice Sirico
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Grazia Signorello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michele Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giorge Manole
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nicola Triglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Massimo Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanna Gallo.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biffi, A., Gallo, G., Fernando, F. et al. Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. J Hum Hypertens 36, 308–314 (2022). https://doi.org/10.1038/s41371-021-00528-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41371-021-00528-1

This article is cited by

Search

Advanced search

Quick links